David J. Loskutoff

David J. Loskutoff's AcademicInfluence.com Rankings

David J. Loskutoff

Philosophy

#5164

World Rank

#7896

Historical Rank

Logic

#2487

World Rank

#3487

Historical Rank

philosophy Degrees

David J. Loskutoff

Biology

#6899

World Rank

#9711

Historical Rank

Cell Biology

#245

World Rank

#253

Historical Rank

Molecular Biology

#746

World Rank

#763

Historical Rank

Biochemistry

#915

World Rank

#1023

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

David J. Loskutoff's Degrees

PhD Biochemistry Stanford University
Doctorate Medicine Stanford University

Why Is David J. Loskutoff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David J. Loskutoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Monocyte chemoattractant protein 1 in obesity and insulin resistance (2003) (1155)
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. (1994) (746)
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. (1992) (584)
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. (1988) (552)
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. (1985) (548)
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? (1996) (471)
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. (1991) (457)
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. (1989) (457)
Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. (1977) (451)
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. (1984) (401)
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. (2001) (390)
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. (1984) (375)
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. (1983) (364)
Cultured bovine endothelial cells produce both urokinase and tissue- type plasminogen activators (1982) (359)
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. (1996) (351)
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies (2001) (337)
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. (1986) (333)
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. (1991) (325)
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. (1986) (319)
Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins (2003) (304)
Elevated Expression of Transforming Growth Factor-β in Adipose Tissue from Obese Mice (1997) (296)
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease (2005) (289)
The adipocyte and hemostatic balance in obesity: studies of PAI-1. (1998) (285)
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. (1989) (244)
Leptin Promotes Vascular Remodeling and Neointimal Growth in Mice (2004) (233)
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. (1985) (227)
Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. (1998) (220)
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. (1988) (219)
Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1 (1999) (216)
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. (1996) (215)
Regulation of PAI-1 gene expression (1991) (210)
Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice (1996) (206)
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. (1988) (200)
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. (1986) (199)
Tissue Distribution of Factor VIII Gene Expression In Vivo – A Closer Look (2001) (194)
Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. (1998) (193)
Angiogenesis in an in vivo model of adipose tissue development (2004) (191)
The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1* (2004) (186)
Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice (2001) (182)
Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. (1989) (181)
Regulation of cell adhesion by PAI‐1 (1999) (180)
Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice (2001) (178)
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. (1995) (176)
Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide (1995) (175)
Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. (1985) (172)
Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. (1987) (171)
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. (1992) (165)
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. (1985) (164)
Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. (1993) (158)
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. (1984) (157)
Plasminogen activator inhibitor-1 is a major stress-regulated gene: Implications for stress-induced thrombosis in aged individuals (2002) (155)
Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. (1991) (153)
Urokinase-Type Plasminogen Activator Plays a Critical Role in Angiotensin II–Induced Abdominal Aortic Aneurysm (2003) (149)
Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. (1995) (148)
Tissue factor gene expression in the adipose tissues of obese mice. (1998) (145)
Plasminogen Has a Broad Extrahepatic Distribution (2002) (141)
PAI-1, fibrosis, and the elusive provisional fibrin matrix. (2000) (139)
Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. (1988) (137)
Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor (1987) (136)
EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. (2005) (135)
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. (1993) (134)
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. (1994) (132)
Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. (1989) (127)
Inactivation of plasminogen activator inhibitor by oxidants. (1986) (123)
Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin (2001) (121)
Detection of vitronectin mRNA in tissues and cells of the mouse. (1991) (120)
Regulation of PAI-1 Gene Expression In Vivo (1993) (117)
Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. (2004) (115)
Structural and Functional Analysis of the Plasminogen Activator Inhibitor-1 Binding Motif in the Somatomedin B Domain of Vitronectin* (1996) (113)
Fibrinolytic System of Vascular Endothelial Cells (1988) (113)
Abnormal Expression of Type 1 Plasminogen Activator Inhibitor and Tissue Factor in Severe Preeclampsia (1998) (111)
The fibrinolytic system of the vascular wall. (1985) (111)
Domain 2 of the Urokinase Receptor Contains an Integrin-interacting Epitope with Intrinsic Signaling Activity (2005) (111)
Tissue factor expression during human and mouse development. (1996) (109)
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. (1994) (108)
Fibrinolytic pathways and the endothelium. (1987) (107)
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. (1993) (107)
Comparative studies of the fibrinolytic activity of cultured vascular cells. (1979) (102)
Distinct antithrombotic consequences of platelet glycoprotein Ibα and VI deficiency in a mouse model of arterial thrombosis (2006) (101)
Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. (1987) (101)
Replication of dengue and junin viruses in cultured rabbit and human endothelial cells (1978) (101)
Inhibition of Endogenous Leptin Protects Mice From Arterial and Venous Thrombosis (2004) (101)
Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. (1994) (100)
An Inhibitor Of Plasminogen Activator In Rabbit Endothelial Cells (1981) (100)
Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. (1979) (100)
Human Endothelial Cells Produce IL‐6 (1989) (98)
Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1 (2003) (97)
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. (1999) (95)
Regulation of tissue factor gene expression in obesity. (2001) (89)
Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. (1989) (87)
Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen Activator (2002) (86)
Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. (2002) (86)
Unexpected Role of Plasminogen Activator Inhibitor 1 in Cell Adhesion and Detachment (2004) (85)
Molecular mechanisms of tumor necrosis factor‐α‐mediated plasminogen activator inhibitor‐1 expression in adipocytes (2005) (85)
Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor (1990) (83)
Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. (2002) (79)
Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. (1997) (77)
Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. (1985) (76)
Insulin Continues to Induce Plasminogen Activator Inhibitor 1 Gene Expression in Insulin-Resistant Mice and Adipocytes (2000) (76)
Vitronectin gene expression in vivo. Evidence for extrahepatic synthesis and acute phase regulation. (1994) (75)
The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator (1990) (74)
Kinetic Analysis of the Interaction between Vitronectin and the Urokinase Receptor* (2002) (73)
Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms. (1988) (73)
The PAI-1/Vitronectin Interaction: Two Cats in a Bag? (1995) (71)
Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-resistant by Treatment with Tumor Necrosis Factor-α* (2003) (70)
Critical Role of Integrin α5β1 in Urokinase (uPA)/Urokinase Receptor (uPAR, CD87) Signaling* (2003) (69)
Plasminogen activator inhibitors. (1991) (67)
SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. (1991) (67)
Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. (1988) (66)
Distribution of vitronectin mRNA during murine development (1995) (65)
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. (1980) (65)
Identification and regulation of tissue plasminogen activator activity in rat cumulus-oocyte complexes. (1986) (64)
Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. (1990) (64)
The Prothrombotic Effects of Leptin (2001) (63)
Type 1 plasminogen activator inhibitor. (1989) (62)
Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. (1991) (58)
Type 1 Plasminogen Activator Inhibitor Induces Multimerization of Plasma Vitronectin (1996) (57)
Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. (1993) (57)
Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells (1988) (55)
Protein C inhibitor is expressed in tubular cells of human kidney. (1994) (54)
Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. (1995) (54)
PLASMINOGEN ACTIVATOR INHIBITOR (1987) (53)
The leptin receptor system of human platelets (2005) (53)
Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on phages: novel perspectives for structure-function analysis by error-prone DNA synthesis. (1993) (52)
Plasminogen activator inhibitors regulate cell adhesion through a uPAR‐dependent mechanism (2009) (52)
Extrahepatic expression and regulation of protein C in the mouse. (1998) (51)
Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. (1995) (49)
Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. (1989) (49)
Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. (1991) (48)
Localization of vitronectin in the normal and atherosclerotic human vessel wall (1997) (47)
Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells (1991) (46)
Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. (1988) (46)
Leptin signalling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases Cγ2 and A2 (2007) (45)
The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. (2001) (45)
REGULATION OF PLASMINOGEN ACTIVATOR PRODUCTION BY CULTURED ENDOTHELIAL CELLS * (1982) (45)
Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. (1994) (45)
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. (1997) (45)
Serum-mediated suppression of cell-associated plasminogen activator activity in cultured endothelial cells (1980) (45)
The Dexamethasone-Induced Inhibitor of Plasminogen Activator in Hepatoma Cells Is Antigenically-Related to an Inhibitor Produced by Bovine Aortic Endothelial Cells (1986) (44)
Effects of acidified fetal bovine serum on the fibrinolytic activity and growth of cells in culture (1978) (44)
Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. (2002) (43)
Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. (2002) (41)
Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. (2004) (40)
Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. (1998) (40)
Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. (1989) (40)
Expression of Transforming Growth Factor-β and Tumor Necrosis Factor-α in the Plasma and Tissues of Mice with Lupus Nephritis (2000) (40)
Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. (1993) (39)
Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide (1997) (39)
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. (2003) (38)
The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis (1990) (38)
Regulation of type I plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. (1991) (38)
Denaturant-induced stimulation of the beta-migrating plasminogen activator inhibitor in endothelial cells and serum. (1986) (36)
Plasminogen activator inhibitor-type I is a major biosynthetic product of retinal microvascular endothelial cells and pericytes in culture. (1989) (35)
Regulation of Murine Protein C Gene Expression In Vivo: Effects of Tumor Necrosis Factor-α, Interleukin-1, and Transforming Growth Factor-β (1999) (34)
Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells (1983) (33)
The Fat Mouse: A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM (2000) (33)
Induction of plasminogen activator inhibitor‐1 (PAI‐1) gene expression in adipocytes by thiazolidinediones (2001) (32)
Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells. (1982) (32)
[26] Plasminogen activators and their inhibitors (1988) (31)
The fibrinolytic system of cultured endothelial cells: deciphering the balance between plasminogen activation and inhibition (1985) (31)
Fibrinolytic system of cultured endothelial cells: Regulation by plasminogen activator inhibitor (1986) (30)
Accumulation of Type 1 Plasminogen Activator Inhibitor and Vitronectin at Sites of Cellular Necrosis and Inflammation (1992) (30)
Highly sulfated glycosaminoglycans augment the cross-linking of vitronectin by guinea pig liver transglutaminase. Functional studies of the cross-linked vitronectin multimers. (1990) (29)
Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice. (1995) (28)
Hemostatic Gene Expression and Vascular Disease in Obesity: Insights from Studies of Genetically Obese Mice (1999) (28)
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. (1997) (28)
Identification of the Disulfide Bonds in the Recombinant Somatomedin B Domain of Human Vitronectin* (2002) (27)
Gene Expression During the Development of Bacillus subtilis Bacteriophage φ29 I. Analysis of Viral-Specific Transcription by Deoxyribonucleic Acid-Ribonucleic Acid Competition Hybridization (1973) (26)
Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. (1995) (25)
Abnormalities in the Fibrinolytic System of the Vascular Wall Associated with Atherosclerosis (1994) (24)
Characterization of Two Monoclonal Antibodies Against Human Tissue-Type Plasminogen Activator (1985) (24)
A slice of PAI. (1993) (23)
Gene Expression During the Development of Bacillus subtilis Bacteriophage φ29 II. Resolution of Viral-Specific Ribonucleic Acid Molecules (1973) (23)
Intracellular plasminogen activator activity in growing and quiescent cells (1978) (23)
Properties of plasminogen activators produced by endothelial cells (1984) (23)
Inhibitors of Urokinase and Thrombin in Cultured Neural Cells (1991) (22)
Contribution of leptin receptor N-linked glycans to leptin binding. (2008) (22)
Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. (1989) (22)
Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis (1994) (22)
A Direct, Plasmin Independent Assay For Plasminogen Activation (1984) (22)
Human hepatoma cell line plasminogen activator. (1983) (22)
Immunoelectron Microscopic Localization of Type 1 Plasminogen Activator Inhibitor in the Extracellular Matrix of Transforming Growth Factor‐β‐Activated Endothelial Cells (1992) (20)
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. (1996) (20)
Differential Regulation of Vitronectin in Mice and Humans in Vitro(*) (1996) (18)
Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. (1983) (18)
Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin (2005) (17)
Expression of Fibrinolytic Genes in Tissues from Human Atherosclerotic Aneurysms and from Obese Mice (1997) (17)
Fibrinolytic Components of Cultured Endothelial Cells (1982) (16)
The Fibrinolytic System of Cultured Endothelial Cells (1987) (16)
Obesity enhances the induction of plasminogen activator inhibitor‐1 by restraint stress: a possible mechanism of stress‐induced renal fibrin deposition in obese mice (2005) (16)
A comparison between activated protein C and des-1-41-light chain-activated protein C in reactions with type 1 plasminogen activator inhibitor. (1989) (16)
A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin. (2001) (15)
Messenger RNA for plasminogen activator inhibitor. (1986) (15)
Renal expression of fibrinolytic genes and tissue factor in a murine model of renal disease as a function of age. (1998) (15)
A Monoclonal Antibody that Does Not Recognize Tissue-Type Plasminogen Activator Bound to Its Naturally Occurring Inhibitor (1986) (13)
INTERLEUKIN 1 (IL-1) AND TUMOR NECROSIS FACTOR (TNF) ACTIVATION OF VASCULAR ENDOTHELIUM: EFFECTS ON PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) AND TISSUE-TYPE PLASMINOGEN ACTIVATOR (tPA) (1987) (12)
PAI-1 inhibits neointimal formation after arterial injury in mice: a new target for controlling restenosis? (1997) (12)
The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule. (2006) (12)
Plasminogen activators and their inhibitors. (1988) (12)
Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin aCv3 to Adhere to Lymph Node Vitronectin (2013) (12)
The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin (2001) (12)
Effect of Activated Protein C on the Fibrinolytic Components Released by Cultured Bovine Aortic Endothelial Cells (1988) (12)
Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis. (2000) (12)
Evidence that extrahepatic cells express vitronectin mRNA at rates approaching those of hepatocytes (1996) (9)
Cloning and sequence of a cDNA coding for the human a-migrating endothelial-cell-type plasminogen activator inhibitor (9)
Glomerular Extracellular Matrix Accumulation in Experimental Anti-GBM Ab Glomerulonephritis (2000) (8)
in Human Platelets (1984) (7)
Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of the SSC Fibrinolysis Subcommittee 1990. (1990) (7)
Detection of Vitronectin by Ligand Blotting with Type 1 Plasminogen Activator Inhibitor (1990) (6)
Membrane characteristics of cultured endothelial cells: identification of gap junction. (1978) (6)
Regulation of Plasminogen Gene Expression (2003) (6)
Analysis of PAI‐1 Gene Expression in Vivo Using in Situ Hybridization (1994) (5)
EFFECT OF TRANSFORMING GROWTH FACTORβ(TGFβ) ON THE FIBRINOLYTIC SYSTEM OF CULTURED BOVINE AORTIC ENDOTHELIAL CELLS (BAEs) (1987) (4)
Activation of Hageman factor by cultured rabbit endothelial cells (1984) (4)
Effect Of Thrombin On The Production Of Plasminogen Activator By Endothelial Cells (1981) (4)
The Biochemistry, Cell and Molecular Biology of Type 1 Plasminogen Activator Inhibitor (1991) (3)
61 Elevated PAI-1 and tissue factor gene expression in obese mice: A possible mechanism for the increased risk for cardiovascular disease associated with obesity (1997) (3)
Distribution of Vitronectin mRNA During (1995) (2)
40 Regulation of plasminogen activator inhibitor type 1 (PAI-1) gene expression in cultured bovine aortic endothelial cells (BAES) (1988) (2)
Analysis of the interaction between type 1 plasminogen activator inhibitor (PAI-1) and its binding protein vitronectin (VN) (1989) (2)
A Role for Adipocyte-Enriched Transcription Factor, PPAR-γ, in Up-Regulation of PAI-1 Gene Expression during Adipogenesis. (2004) (2)
Carboxypeptidases: new regulators of plasminogen activation in vivo? (1995) (2)
347 Serum-derived lipopolysaccharide (LPS) binding factors enhance the LPS-mediated induction of type 1 plasminogen activator inhibitor (PAI-1) in endothelial cells (1988) (2)
Preparation of tissue culture serum lacking α2‐macroglobulin (1978) (2)
Expression of fibrinolytic components in plasmas and placentas from patients with trophoblastic disease (1994) (1)
ID: 319 Keratinocyte-derived chemokine in adipocyte biology and obesity: Potential role in adipose inflammation and glucose homeostasis. (2006) (1)
Multiple Molecular Forms Of Plasminogen Activator Produced By Cultured Bovine Endothelial Cells (1981) (1)
Regulation of plasminogen activator inhibitor-1 (PAI-1) gene expression in adipose tissue and in cultured adipocytes (1994) (1)
Evaluation of second messengers and protein kinases involved in regulation of type 1 plasminogen activator inhibitor synthesis (1989) (1)
Sesion 22: Biochemistry of PAI-1274 Characterization of the immune form of plasminogen activator inhibitor type-1 (PAI-1) present in cultured bovine aortic endothelial cells (Baes) (1988) (1)
The regulation of uterine tissue factor by estrogen (1995) (0)
Cytokine regulation of the murine vitronectin gene: Identification of regulatory sequences for interleukin 6 (1994) (0)
The Stress-Induced PAI-1 Expression Is Enhanced in Obese Mice: A Possible Mechanism of Stress-Associated Thrombosis in Obese Subjects. (2004) (0)
Scientific and Standardization Committee Communications Recommendations for the Nomenclature of Mutant Fibrinolytic Genes and Their Proteins (1990) (0)
functionally active type 1 plasminogen activator inhibitor Extracellular matrix of cultured bovine aortic endothelial cells contains (2010) (0)
The Role of Type 1 Plasminogen Activator Inhibitor in the Regulation of the Fibrinolytic System of the Normal and Atherosclerotic Vessel Wall (1991) (0)
35 Pai-1 regulates u-PAR- and integrin-mediated adhesion of cells to vitronectin (1997) (0)
Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse (2003) (0)
Medical control of abdominal aortic aneurysm expansion rate. (1996) (0)
Transcriptional regulation of the type 1 plasminogen activator inhibitor gene: Functional analysis of the glucocorticoid responsive elements (1989) (0)
Structural and biochemical evidence for disulfide bond heterogeneity in active forms of the somatomedin B domain of human vitronectin (2004) (0)
6 Interaction of tissue-type plasminogen activator (t-PA) with endothelial cells (ECs): Effect on type 1 plasminogen activator inhibitor (PAI-1) (1988) (0)
10 Induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression by thiazolidinediones during adipocyte differentiation (1997) (0)
(plasminogen activators/plasminogen activator inhibitor/cell-mediate (2016) (0)
The generation of proteases by reactive astrocytes (1995) (0)
Monoclonal antibodies to bovine type 1 plasminogen activator inhibitor (PAI-1): Demonstration of multiple antigenic conformations and development of immunoassays to quantitate PAI-1 in cultured cells (1989) (0)
Subject Index, Vol. 18, 1988 (1988) (0)
In situ hybridization: new approaches for the in vivo localization of fibrinolytic components (1993) (0)
70 Characterization of monoclonal antibodies (MABS) to various conformations of bovine type 1 plasminogen activator inhibitor (PAI-1) (1988) (0)
Plasminogen Activator Enzymes and Inhibitors in Epithelial Biology and Pathology (2019) (0)
Replication ofDengueandJuninViruses inCultured Rabbit andHumanEndothelial Cellst (1978) (0)
Regulation of Vascular Fibrinolysis by Type 1 Plasminogen Activator Inhibitor (1995) (0)
Contents, Vol. 18, 1988 (1988) (0)
Ultrastructural localization of type 1 plasminogen activator inhibitor in association with extracellular matrix cell adhesion sites of endothelial cells (1989) (0)
Abdominal Aortic Aneurysm Induced − Urokinase-Type Plasminogen Activator Plays a Critical Role in Angiotensin II (2003) (0)
Increased type1plasminogen activator inhibitor geneexpression in atherosclerotic humanarteries (1992) (0)
THE STRUCTURE OF THE HUMAN ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) GENE: NON-RANDOM POSITIONING OF INTRONS (1987) (0)
A monoclonal antibody which interferes with the binding of type 1 plasminogen activator inhibitor (PAI-1) to its binding protein vitronectin (VN) (1989) (0)
Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-I in Obese Mice' (2007) (0)
Rapid, reversible rounding and aggregation of Rous sarcoma virus-infected chicken fibroblasts induced by a plasma macromolecule. (1980) (0)
THE EXTRACELLULAR MATRIX (ECM) OF CULTURED BOVINE AORTIC ENDOTHELIAL CELLS (BAEs) CONTAINS FUNCTIONALLY ACTIVE TYPE I PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) (1987) (0)
The Fibrinolytic System of Cultured Bovine Aortic Endothelial Cells (1987) (0)
Characterization of the Fibrinolytic Components Specified by Vascular Endothelial Cells (1977) (0)
International Society for Fibrinolysis and Thrombolysis (ISFT) Minutes of the General Meeting, Leuven, Belgium, September 21, 1994 (1994) (0)
Preparation of tissue culture serum lacking alpha2-macroglobulin. (1978) (0)
Inhibitory role for vitronectin in angiotensin II-induced vascular fibrosis (2001) (0)
Localization of plasminogen activator inhibitor (PAI-I) and vitronectin (Vn) in the atherosclerotic vessel wall (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David J. Loskutoff?

David J. Loskutoff is affiliated with the following schools:

David J. Loskutoff's Academic­Influence.com Rankings

David J. Loskutoff's Degrees

Why Is David J. Loskutoff Influential?

David J. Loskutoff's Published Works

Published Works

What Schools Are Affiliated With David J. Loskutoff?

David J. Loskutoff's AcademicInfluence.com Rankings